LAVAL, QC, Feb. 18, 2021 /PRNewswire/ -- Bausch Health
Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its
gastroenterology (GI) business, Salix Pharmaceuticals, ("Salix"),
one of the largest specialty pharmaceutical companies in the world
committed to the prevention and treatment of gastrointestinal
diseases, today announced the opening of the application period for
the 2021 Salix Gastrointestinal Health Scholars Program. The
program, in its second year, will award 10 outstanding students
living with GI disease a scholarship of up to $10,000 to help them pursue their higher
education goals.
"We're proud to continue the Salix Gastrointestinal Health
Scholars Program to provide financial assistance to students who
are balancing the challenges of living with GI disease while also
pursuing their higher education goals, and we look forward to
honoring 10 deserving students later this year," said Robert Spurr, president, Salix.
To apply for the 2021 scholarship, students are required to
write an essay that describes the impact having a diagnosed GI
condition has had on their life, as well as the role that a health
care provider played in helping to manage their condition.
Scholarships are offered to school applicants or current attendees
of a two- or four-year college, university, or an advanced
(post-high school) vocational or technical school for the 2021-2022
academic year, and are available in four categories:
- Undergraduate Scholar Awards for students pursuing
undergraduate degrees
- Graduate Scholar Awards for students pursuing
graduate degrees
- Working Parent's Scholar Award for students who are
parents pursuing undergraduate, vocational/technical or graduate
degrees
- Single Parent's Scholar Award for students who are
single parents pursuing undergraduate, vocational/technical or
graduate degrees
Students can apply for the Salix Gastrointestinal Health
Scholars Program through May 31, 2021. Winners will be
announced in July 2021. To learn more about the scholarship,
including eligibility criteria, terms and conditions, please
visit www.salix.com/scholarship.
The Salix Gastrointestinal Health Scholars Program Scholarship
program is funded through the Bausch Foundation.
About the Bausch Foundation
The Bausch Foundation was
established in 2017 to improve the lives of patients globally by
providing access to safe, effective medicines and by financially
supporting health care education and causes. Since its
inception, the Bausch Foundation has contributed millions of
dollars' worth of financial and product donations to charitable
health organizations.
About Salix
Salix Pharmaceuticals is one of the
largest specialty pharmaceutical companies in the world committed
to the prevention and treatment of gastrointestinal diseases. For
more than 30 years, Salix has licensed, developed, and marketed
innovative products to improve patients' lives and arm health care
providers with life-changing solutions for many chronic and
debilitating conditions. Salix currently markets its product line
to U.S. health care providers through an expanded sales force that
focuses on gastroenterology, hepatology, pain specialists and
primary care. Salix is headquartered in Bridgewater,
New Jersey. For more information
about Salix, visit www.Salix.com and connect with us on
Twitter and LinkedIn.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.bauschhealth.com.
Forward-looking Statements
This news release may
contain forward-looking statements, which may generally be
identified by the use of the words "anticipates," "expects,"
"intends," "plans," "should," "could," "would," "may," "believes,"
"estimates," "potential," "target," or "continue" and variations or
similar expressions. These statements are based upon the current
expectations and beliefs of management and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to, the
risks and uncertainties discussed in Bausch Health's most recent
annual report on Form 10-K and detailed from time to time in Bausch
Health's other filings with the U.S. Securities and Exchange
Commission and the Canadian Securities Administrators, which
factors are incorporated herein by reference. They also include,
but are not limited to, risks and uncertainties caused by or
relating to the evolving COVID-19 pandemic, and the fear of that
pandemic and its potential effects, the severity, duration and
future impact of which are highly uncertain and cannot be
predicted, and which may have a material adverse impact on Bausch
Health, including but not limited to its project development
timelines, and costs (which may increase). Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch Health undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
©2021 Salix Pharmaceuticals or its
affiliates.
SAL.0032.USA.21
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
(908)
927-1198
|
(877) 281-6642 (toll
free)
|
|
|
Karen Paff
|
|
Karen.paff@salix.com
|
|
(908)
927-1190
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/salix-announces-2021-gastrointestinal-health-scholars-program-301230935.html
SOURCE Bausch Health Companies Inc.